AnaptysBio Inc

AIM ImmunoTech Inc.

AbbVie Inc

Alpine Immune Sciences

Aduro Biotech

Cabaletta Bio

Immunome, Inc.

Allakos Inc

Nektar Therapeutics

Short interest: 24.54% of float, squeeze risk: HIGH

Dilution score: 21/100 (LOW), 24.0 months cash

313 PubMed publications found for AnaptysBio

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.

Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis.

Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance.

Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate-to-Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials.

Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis.

Dilution score: 15/100 (LOW), 999.0 months cash

312 PubMed publications found for AnaptysBio

Short interest: 22.82% of float, squeeze risk: HIGH

311 PubMed publications found for AnaptysBio

Short interest: 25.33% of float, squeeze risk: HIGH

SW convergence: 36/100 (Bearish Convergence), 1 bullish / 1 bearish signals

Short interest: 25.53% of float, squeeze risk: HIGH

310 PubMed publications found for AnaptysBio

Therapeutic Approaches for Cutaneous Lupus Erythematosus: a Changing Landscape of Clinical Trials.

Short interest: 25.84% of float, squeeze risk: HIGH

Dilution score: 17/100 (LOW), 999.0 months cash

Short interest: 23.79% of float, squeeze risk: HIGH

309 PubMed publications found for AnaptysBio

SW convergence: 36/100 (Bearish Convergence), 2 bullish / 2 bearish signals

308 PubMed publications found for AnaptysBio

<article class="bts-verified-summary" data-ticker="ANAB">
<p>AnaptysBio Inc (ANAB) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-2">[2]</a></sup>, including 2 Phase 2<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>ANAB has 2 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-3">[3]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22AnaptysBio+Inc%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22AnaptysBio+Inc%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-3">SEC EDGAR · 0001370053 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22ANAB%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR — 0001370053

AnaptysBio Inc (ANAB) — BioTechSigns Verified Summary

AnaptysBio Inc (ANAB) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[2], including 2 Phase 2[1].

ANAB has 2 Form 4 insider filings recorded at the SEC in the past 30 days[3].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22AnaptysBio+Inc%22&aggFilters=status%3Arec%2Cact
[2] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22AnaptysBio+Inc%22&aggFilters=status%3Arec%2Cact
[3] SEC EDGAR, 0001370053. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22ANAB%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe Rheumatoid Arthritis (RA)

A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)